Pakistan's Advantage in Hepatitis Delta & MASH Trials
IQVIA2026-01-0216 页
Do 340B Contract Pharmacies Really 'Increase Access' for 340B Patients?
IQVIA2026-01-1714 页
神经介入高值耗材行业研究报告
北京大学医学部2026-03-0737 页
新药医保落地背景下中国痛风及高尿酸血症诊疗格局与市场趋势洞察报告
摩熵咨询2026-06-2832 页
Is One Brand Enough for a Global Market? Second-brand strategy in emerging APAC markets: Lessons, trade-offs, and a practical playbook for MNCs trying to address access issues with sustainability
IQVIA2026-07-1024 页